IsoRay teams up with Russia firm to open routes for prostate cancer tech
This article was originally published in Clinica
IsoRay Medical, developer of the Proxcelan Cesium-131 brachytherapy seeds, is set to capitalise on the opportunities in the fast-growing East European healthcare market, after having bought a 30% ownership in a newly-formed Russian medical isotope manufacturer UralDial.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.